Found: 6
Select item for more details and to access through your institution.
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1197, doi. 10.1007/s00262-018-2178-0
- By:
- Publication type:
- Article
Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
- Published in:
- Cancer Immunology, Immunotherapy, 2017, v. 66, n. 11, p. 1399, doi. 10.1007/s00262-017-2033-8
- By:
- Publication type:
- Article
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2011, v. 66, n. 9, p. 2099
- By:
- Publication type:
- Article
Dose standardisation of anticancer drugs.
- Published in:
- International Journal of Clinical Pharmacy, 2011, v. 33, n. 2, p. 221, doi. 10.1007/s11096-010-9478-6
- By:
- Publication type:
- Article
Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1–Infected Patients: A Randomized Open-Label Trial.
- Published in:
- Clinical Infectious Diseases, 2009, v. 49, n. 8, p. 1259, doi. 10.1086/605674
- By:
- Publication type:
- Article
Gemcitabine–Oxaliplatin Combination in Heavily Pretreated Metastatic Breast Cancer: A Pilot Study on 43 Patients.
- Published in:
- Breast Journal, 2007, v. 13, n. 2, p. 165, doi. 10.1111/j.1524-4741.2007.00391.x
- By:
- Publication type:
- Article